These findings suggest that AT1R overexpression is an independent adverse prognosticator for patients with ESCC and that angiotensin II/AT1R signaling stimulates ESCC growth, in part through mTOR activation. This evidence concerns the gene AGTR1 and esophageal squamous cell carcinoma.